Vor Biopharma Inc. Common Stock (VOR)
Stock · NASDAQ · Health Care
$18.03as of 10/16/2026
Price chart
Active signals
Support level
$17.91
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
VOR Signal Track Record
How signals performed across all stocks →What VOR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 23 | -5.6% | 26% | September 2, 2026 |
| Volume Spike | 19 | -10.2% | 42% | September 16, 2026 |
| Bollinger Band Breakdown | 19 | -2.9% | 42% | September 23, 2026 |
| 200-Day Moving Average TouchActive now | 4 | -33.0% | 0% | October 30, 2025 |
| Any 20-session window (baseline) | -3.5% | 41% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About VOR
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for t…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 76
- Website
- www.vorbio.com/
Fundamentals
- 1-day range
- $18$19.45
- Market cap
- $1.28B
- P/E (trailing)
- 1.82
- P/E (forward)
- -4.75
- EPS (trailing)
- $-43.00
- Dividend yield
- —
- Beta
- 1.70
- Avg. volume
- 969.1K
52-week range
$6.5$33.42
Next earnings: November 12, 2026 · EPS estimate $-0.72confirmed
Forecasts
8 analyst ratings
Buy 85%
Hold 15%
Sell 0%
1-year price forecast
High
$50
+177.3%
Median
$40
+121.9%
Low
$27
+49.8%
Vor Biopharma Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- VORVor Biopharma Inc. Common Stock$18.03▼ 6.77%Market cap $1.28BP/E 1.82$6.5$33.42
- NVAXNovavax Inc. Common Stock$11.26▼ 12.17%Market cap $1.27BP/E —$6.2$13.39
- IMTXImmatics N.V. Ordinary Shares$6.73▼ 5.74%Market cap $1.26BP/E —$6.73$12.41
- INBXInhibrx Biosciences Inc. Common Stock$89.83▼ 0.74%Market cap $1.26BP/E —$28.16$155.29
- GLUEMonte Rosa Therapeutics Inc. Common Stock$9.74▼ 3.75%Market cap $1.33BP/E —$8.94$25.77
- ALVOAlvotech Ordinary Shares$5▼ 5.84%Market cap $1.19BP/E —$2.94$9.05
- MGTXMeiraGTx Holdings plc Ordinary Shares$9.28▼ 6.17%Market cap $1.18BP/E 11.93$6.62$15.35
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| VOR Vor Biopharma Inc. Common Stock | $1.28B | 1.82 | $18.03 | ▼ 6.77% | $6.5$33.42 |
| NVAX Novavax Inc. Common Stock | $1.27B | — | $11.26 | ▼ 12.17% | $6.2$13.39 |
| IMTX Immatics N.V. Ordinary Shares | $1.26B | — | $6.73 | ▼ 5.74% | $6.73$12.41 |
| INBX Inhibrx Biosciences Inc. Common Stock | $1.26B | — | $89.83 | ▼ 0.74% | $28.16$155.29 |
| GLUE Monte Rosa Therapeutics Inc. Common Stock | $1.33B | — | $9.74 | ▼ 3.75% | $8.94$25.77 |
| ALVO Alvotech Ordinary Shares | $1.19B | — | $5 | ▼ 5.84% | $2.94$9.05 |
| MGTX MeiraGTx Holdings plc Ordinary Shares | $1.18B | 11.93 | $9.28 | ▼ 6.17% | $6.62$15.35 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Vor Biopharma (VOR) Could Be 52% Undervalued As Phase 3 gMG Data Draw FocusYahoo · 10/8/2026
- Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/5/2026
- Durable MG Responses From Telitacicept Could Be A Game Changer For Vor Biopharma (VOR)Yahoo · 10/4/2026
- Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia GravisYahoo · 9/29/2026
- Vor Bio Announces Data Phase 3 Trial Of Telitacicept By Its RemeGen Partner Demonstrates Over 95% Participants Achieved At Least 5-Point MG-ADL Improvement Over 48 WeeksBenzinga · 9/29/2026
- Vor Biopharma: A Funded Replication Story With Franchise PotentialSeekingAlpha · 9/18/2026
- Sjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2 Inhibitors, and Cell Therapies | DelveInsightYahoo · 9/16/2026
Insider Activity
Insider Actions →Acquired
2.60M
Disposed
337.3K
- RA CAPITAL MANAGEMENT, L.P. · October 2, 2026 · Option Exercise500 @ $12.8
- RA CAPITAL MANAGEMENT, L.P. · August 24, 2026 · Option Exercise1.5K @ $3.74
- RA CAPITAL MANAGEMENT, L.P. · July 16, 2026 · X2.10M @ $0.002
- RA CAPITAL MANAGEMENT, L.P. · July 16, 2026 · Sale213 @ $19.75
- ZACCARDELLI DAVID · July 7, 2026 · Grant42.7K
- Joustra Wouter · June 11, 2026 · Grant57.2K
- Levin Andrew David · June 11, 2026 · Grant57.2K
- Detheux Michel · June 11, 2026 · Grant57.2K
- Namouni Fouad · June 11, 2026 · Grant56.5K
- Cumbo Alexander · June 11, 2026 · Grant56.3K
- Beckman Daniella · June 11, 2026 · Grant53.3K
- Kalir Erez · June 11, 2026 · Grant57.2K
- RA Capital Healthcare Fund LP · June 11, 2026 · Grant57.2K
- RA Capital Healthcare Fund LP · April 22, 2026 · Sale165.2K @ $15.77
- RA Capital Healthcare Fund LP · April 20, 2026 · Sale172.0K @ $15.77
Institutional Ownership
March 31, 2026
- Total shares held
- 40.42M
- Total value held
- $715.96M
- Institutional holders
- 77
Top holders this quarter
- Unknown5.67M
- Unknown5.40M
- Unknown4.12M
- Unknown3.04M
- Unknown2.54M
- Unknown1.93M
- Unknown1.75M
- Unknown1.75M
- Unknown1.54M
- Unknown1.43M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Vor Biopharma Phase 3 data draws valuation focus
Recent analysis suggests Vor Biopharma may be undervalued as attention shifts to its Phase 3 data for generalized myasthenia gravis. This clinical milestone is central to the stock's current narrative, with analysts maintaining a wide range of price targets. The company's low trailing P/E ratio provides additional context for its current valuation relative to its 52-week trading range.
Vor Biopharma Phase 3 data draws valuation focus. Recent analysis suggests Vor Biopharma may be undervalued as attention shifts to its Phase 3 data for generalized myasthenia gravis. This clinical milestone is central to the stock's current narrative, with analysts maintaining a wide range of price targets. The company's low trailing P/E ratio provides additional context for its current valuation relative to its 52-week trading range.